Analysts Set Expectations for ARWR FY2030 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at B. Riley issued their FY2030 EPS estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, November 25th. B. Riley analyst M. El-Saadi expects that the biotechnology company will post earnings of $6.48 per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

A number of other brokerages have also commented on ARWR. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Piper Sandler increased their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. The Goldman Sachs Group raised their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 20th. Morgan Stanley upped their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Royal Bank Of Canada increased their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.56.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $57.71 on Thursday. The stock has a fifty day moving average of $38.70 and a 200-day moving average of $25.63. The firm has a market capitalization of $7.98 billion, a P/E ratio of -45.09 and a beta of 1.27. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $59.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Virtus Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. Salomon & Ludwin LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,308 shares during the period. Finally, Federated Hermes Inc. acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 50,000 shares of company stock worth $1,525,000. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.